Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial-Reference-Cited by-同舟云学术

Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial

Published:1984-07 Issue:1 Volume:50 Page:45-49
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Anderson H,Scarffe J H,Sutton R N,Hickmott E,Brigden D,Burke C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc1984138.pdf

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group;Annals of Hematology;2024-08-08

2. Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life;Cancers;2023-11-13

3. Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus;Annals of Hematology;2022-01-07

4. Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis;International Journal of Environmental Research and Public Health;2020-11-30

5. Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center;Clinical Lymphoma Myeloma and Leukemia;2019-03